Contezolid

Contezolid
Clinical data
Trade names	Youxitai
Other names	MRX-I
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name (5S)-5-[(1,2-oxazol-3-ylamino)methyl]-3-[2,3,5-trifluoro-4-(4-oxo-2,3-dihydropyridin-1-yl)phenyl]-1,3-oxazolidin-2-one;
CAS Number	1112968-42-9 ;
PubChem CID	25184541 ;
IUPHAR/BPS	10795 ;
DrugBank	DB12796 ;
ChemSpider	34217570 ;
UNII	B669M62ELP ;
KEGG	D11297 ;
ChEMBL	ChEMBL3287379 ;
CompTox Dashboard (EPA)	DTXSID901353186 ;
Chemical and physical data
Formula	C18H15F3N4O4
Molar mass	408.337 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES C1CN(C=CC1=O)C2=C(C=C(C(=C2F)F)N3C[C@@H](OC3=O)CNC4=NOC=C4)F;
	InChI InChI=1S/C18H15F3N4O4/c19-12-7-13(15(20)16(21)17(12)24-4-1-10(26)2-5-24)25-9-11(29-18(25)27)8-22-14-3-6-28-23-14/h1,3-4,6-7,11H,2,5,8-9H2,(H,22,23)/t11-/m0/s1; Key:SULYVXZZUMRQAX-NSHDSACASA-N;

Last updated December 27, 2025

Contezolid (trade name Youxitai) is an antibiotic of the oxazolidinone class.^[1]^[2] It is effective against Staphylococcus aureus , methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pyogenes , Streptococcus agalactiae , and other bacteria.^[3]

In 2021, it was approved by the National Medical Products Administration of China for the treatment of complicated skin and soft tissue infections (cSSTI).^[3]^[4]

A prodrug of contezolid, contezolid acefosamil, which is formulated for IV administration ^[5] is in Phase III clinical trials for diabetic foot infection.^[6]

References

↑ Gordeev MF, Yuan ZY (June 2014). "New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile". Journal of Medicinal Chemistry. 57 (11): 4487–4497. doi:10.1021/jm401931e. PMID 24694071.
↑ Zhao X, Huang H, Yuan H, Yuan Z, Zhang Y (May 2022). "A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections". The Journal of Antimicrobial Chemotherapy. 77 (6): 1762–1769. doi:10.1093/jac/dkac073. PMID 35265985.
1 2 Hoy SM (September 2021). "Contezolid: First Approval". Drugs. 81 (13): 1587–1591. doi:10.1007/s40265-021-01576-0. PMC 8536612 . PMID 34365606.
↑ Mak E (3 June 2021). "Micurx wins China approval for antibacterial contezolid". BioWorld.
↑ Liu J, Wang W, Wang C, Zhang L, Zhang X, Liu S, et al. (July 2022). "Discovery of Antibacterial Contezolid Acefosamil: Innovative O-Acyl Phosphoramidate Prodrug for IV and Oral Therapies". ACS Medicinal Chemistry Letters. 13 (7): 1030–1035. doi:10.1021/acsmedchemlett.2c00191. PMC 9290071 . PMID 35859881.
↑ "Contezolid acefosamil by MicuRx Pharmaceuticals for Diabetic Foot Infection (DFI): Likelihood of Approval". GlobalData. 31 May 2023 – via Pharmaceutical Technology.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Gordeev MF, Yuan ZY (June 2014). "New Potent Antibacterial Oxazolidinone (MRX-I) with an Improved Class Safety Profile". Journal of Medicinal Chemistry. 57 (11): 4487–4497. doi:10.1021/jm401931e. PMID 24694071.

[2] Zhao X, Huang H, Yuan H, Yuan Z, Zhang Y (May 2022). "A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections". The Journal of Antimicrobial Chemotherapy. 77 (6): 1762–1769. doi:10.1093/jac/dkac073. PMID 35265985.

[Hoy-3] 1 2 Hoy SM (September 2021). "Contezolid: First Approval". Drugs. 81 (13): 1587–1591. doi:10.1007/s40265-021-01576-0. PMC 8536612 . PMID 34365606.

[4] Mak E (3 June 2021). "Micurx wins China approval for antibacterial contezolid". BioWorld.

[5] Liu J, Wang W, Wang C, Zhang L, Zhang X, Liu S, et al. (July 2022). "Discovery of Antibacterial Contezolid Acefosamil: Innovative O-Acyl Phosphoramidate Prodrug for IV and Oral Therapies". ACS Medicinal Chemistry Letters. 13 (7): 1030–1035. doi:10.1021/acsmedchemlett.2c00191. PMC 9290071 . PMID 35859881.

[6] "Contezolid acefosamil by MicuRx Pharmaceuticals for Diabetic Foot Infection (DFI): Likelihood of Approval". GlobalData. 31 May 2023 – via Pharmaceutical Technology.

[1]

[2]

[3]

[4]

[5]

[6]